If you have been researching medical weight loss, you have probably heard a lot about semaglutide and tirzepatide. Both are once-weekly injectable medications that can reduce hunger and help people lose weight—but they are not exactly the same.
So, what is the difference between semaglutide and tirzepatide? Does one work better? And how do you know which medication may be right for you?
Here is a simple breakdown of semaglutide vs. tirzepatide for weight loss—without all the confusing medical jargon.
What Is Semaglutide?
Semaglutide belongs to a group of medications called GLP-1 receptor agonists. It acts like a natural hormone your body releases after eating.
This hormone helps:
- Reduce hunger
- Help you feel full sooner
- Keep you feeling satisfied longer
- Slow the movement of food through the stomach
- Improve the way the body manages blood sugar
Semaglutide is the active ingredient in medications such as Wegovy and Ozempic. Wegovy is specifically approved for chronic weight management in eligible patients, while Ozempic is primarily approved for treating type 2 diabetes.
In the STEP 1 clinical trial, adults without diabetes who received semaglutide 2.4 mg along with lifestyle support lost an average of approximately 14.9% of their starting body weight over 68 weeks. Individual results varied, and not everyone lost the same amount.
What Is Tirzepatide?
Tirzepatide works in a similar way, but it targets two hormone pathways instead of one:
- GLP-1, or glucagon-like peptide-1
- GIP, or glucose-dependent insulinotropic polypeptide
Both hormones are involved in appetite, fullness, insulin response, and blood-sugar regulation. Because tirzepatide acts on two pathways, it is sometimes described as a “dual-action” medication.
Tirzepatide is the active ingredient in Zepbound and Mounjaro. Zepbound is approved for chronic weight management in eligible patients, while Mounjaro is primarily approved for type 2 diabetes.
In the SURMOUNT-1 clinical trial, adults without diabetes lost an average of approximately 15% to 20.9% of their starting weight over 72 weeks, depending on the tirzepatide dose used.
Semaglutide vs. Tirzepatide: The Main Difference
The biggest difference is the number of hormone receptors each medication targets:
|
Semaglutide |
Tirzepatide |
|
Activates one hormone pathway |
Activates two hormone pathways |
|
Targets GLP-1 |
Targets GLP-1 and GIP |
|
Taken once weekly |
Taken once weekly |
|
Reduces hunger and increases fullness |
Reduces hunger and increases fullness |
|
Produces significant average weight loss |
Often produces greater average weight loss in clinical trials |
In simple terms, semaglutide works through one appetite-regulating pathway, while tirzepatide works through two.
Does Tirzepatide Cause More Weight Loss Than Semaglutide?
On average, clinical trials suggest that tirzepatide may produce more weight loss than semaglutide at commonly studied doses.
A 2025 head-to-head clinical trial directly compared the two medications in adults with obesity who did not have diabetes. After 72 weeks, participants taking tirzepatide lost an average of approximately 20.2% of their body weight, compared with approximately 13.7% among those taking semaglutide.
That does not mean tirzepatide is automatically the best medication for every person. These numbers are group averages from controlled clinical trials. Your results may be influenced by:
- Your starting weight and health history
- The dose you can comfortably tolerate
- Nutrition and physical activity
- Sleep and stress
- Other medications
- Hormonal or metabolic conditions
- How consistently you follow the treatment plan
- How your individual body responds
Some people do very well with semaglutide and may have no reason to switch. Others may respond more strongly to tirzepatide or tolerate one medication better than the other.
How Much Weight Can You Lose?
There is no guaranteed amount of weight loss with either medication. However, research gives us a general idea of what may be possible when treatment is combined with nutrition, physical activity, and ongoing medical support.
Based on major clinical trials:
- Semaglutide: Approximately 15% average weight loss over 68 weeks
- Tirzepatide: Approximately 15% to 21% average weight loss over 72 weeks, depending on dose
- Direct comparison: Approximately 13.7% with semaglutide versus 20.2% with tirzepatide over 72 weeks
For someone who weighs 250 pounds, a 15% reduction would equal about 37.5 pounds. A 20% reduction would equal about 50 pounds. These examples illustrate percentages only and are not a prediction of an individual patient’s results.
Do Semaglutide and Tirzepatide Have the Same Side Effects?
Because the medications work in similar ways, they share many of the same potential side effects.
The most common side effects include:
- Nausea
- Constipation
- Diarrhea
- Vomiting
- Heartburn or indigestion
- Abdominal discomfort
- Feeling overly full
- Decreased appetite
- Fatigue
Side effects are often more noticeable when treatment begins or after the dose is increased. Starting at a low dose and increasing gradually can help the body adjust.
Eating smaller meals, stopping when comfortably full, limiting greasy or heavy foods, drinking enough water, and prioritizing protein may also help.
Contact your healthcare provider if side effects are severe, persistent, or make it difficult to eat or drink. Severe abdominal pain, repeated vomiting, signs of dehydration, or symptoms of an allergic reaction require prompt medical attention.
Who Should Not Take These Medications?
Semaglutide and tirzepatide are not appropriate for everyone. They should not be used during pregnancy and are generally avoided in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, also called MEN 2.
Extra caution may be necessary if you have a history of:
- Pancreatitis
- Gallbladder disease
- Severe digestive or stomach-emptying problems
- Kidney problems or frequent dehydration
- Diabetic eye disease
- Significant medication allergies
- An eating disorder
People who take insulin or certain diabetes medications may also have a greater risk of low blood sugar and may need medication adjustments.
Tirzepatide can affect the absorption of oral birth-control pills during treatment initiation and after dose increases. Patients using oral contraception should discuss backup or non-oral birth control with their healthcare provider.
A medical consultation is important because your complete health history—not simply how much weight you want to lose—should guide the decision.
Which Medication Has More Health Benefits?
Both medications may improve more than the number on the scale. Weight loss and improved blood-sugar regulation may support better:
- Blood pressure
- Cholesterol and triglyceride levels
- Insulin sensitivity
- Blood-sugar control
- Mobility
- Sleep
- Energy
- Overall metabolic health
Semaglutide has an FDA-approved indication for reducing the risk of cardiovascular death, heart attack, and stroke in certain adults who have cardiovascular disease and are overweight or have obesity.
Tirzepatide is FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity, along with reduced-calorie nutrition and increased physical activity.
These additional indications do not make one medication universally better. They may, however, influence the choice for someone with a particular medical condition.
What Happens If You Stop Taking Semaglutide or Tirzepatide?
Obesity is a chronic medical condition, and these medications usually work best as part of a long-term plan.
When treatment stops, appetite may increase again. Some people regain part of the weight they lost, especially if the factors that contributed to weight gain are still present.
This is not a sign of failure or a lack of willpower. The medication was helping regulate biological signals involved in hunger and fullness. When that support is removed, those signals may return.
Before starting treatment, it is important to discuss:
- Whether long-term treatment is realistic
- What the maintenance plan will look like
- How nutrition and muscle mass will be supported
- What to do if the medication becomes unavailable
- Whether cost or insurance coverage may affect treatment
Can You Switch From Semaglutide to Tirzepatide?
Some patients may be candidates for switching, particularly if they:
- Have reached a weight-loss plateau
- Are not achieving meaningful results
- Cannot tolerate their current medication
- Have a health condition that may favor another option
- Need a different treatment strategy
However, the medications should not be taken together. Switching should be planned by a qualified healthcare professional because the starting dose and timing may depend on your current medication, dose, side effects, and medical history.
Is Semaglutide or Tirzepatide Better?
The honest answer is: the better medication is the one that is safe, effective, tolerable, and sustainable for you.
Tirzepatide produces greater average weight loss in head-to-head research, but semaglutide remains an effective option with extensive clinical evidence. The strongest medication on paper is not necessarily the right medication for every patient.
A provider should consider:
- Your medical history
- Current medications
- Weight-related health conditions
- Previous weight-loss attempts
- Side-effect concerns
- Treatment goals
- Medication availability and cost
- Your response to previous GLP-1 treatment
Medical Weight Loss in Minot, ND
At Bellus Medical in Minot, North Dakota, we understand that weight management is not simply about eating less or trying harder. Appetite, hormones, metabolism, sleep, stress, medications, and underlying health conditions can all influence weight.
Our medical weight-loss consultations are designed to help determine whether semaglutide, tirzepatide, or another approach may be appropriate for you. We also focus on maintaining nutrition, preserving muscle, managing side effects, and creating a plan that can work in real life.
If you are comparing semaglutide vs. tirzepatide for weight loss, the first step is a conversation about your health, goals, and previous experiences.
Contact Bellus Medical to schedule a medical weight-loss consultation.
Bellus Medical
Minot, North Dakota
Call: 701-420-2273
Text: 701-509-5614
Website: bellusmedicalminot.com
This article is intended for general educational purposes and does not replace individualized medical advice. Prescription weight-loss medications should be used only under the supervision of a qualified healthcare professional.
Frequently Asked Questions
Is tirzepatide stronger than semaglutide?
Tirzepatide produced greater average weight loss than semaglutide in a direct clinical trial. However, “stronger” does not always mean safer or more appropriate for a particular patient.
Are semaglutide and tirzepatide insulin?
No. Neither medication is insulin. They imitate naturally occurring hormones that help regulate appetite, digestion, and blood sugar.
How quickly do these medications start working?
Some people notice less hunger within the first few weeks. Weight loss typically occurs gradually as the medication is increased and continued. Results vary considerably between patients.
Can I take semaglutide and tirzepatide together?
No. These medications should not be combined. Doing so may increase side effects and has not been established as safe or effective.
Will I need to diet while taking a GLP-1 medication?
Extreme dieting is not recommended. A balanced eating plan with adequate protein, fiber, fluids, and essential nutrients can support weight loss while helping protect muscle mass and overall health.
Which medication has fewer side effects?
Their common side effects are similar, but individual tolerance varies. One person may feel better on semaglutide, while another may tolerate tirzepatide more easily.
Scholarly Resources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine. 2021;384:989–1002. https://doi.org/10.1056/NEJMoa2032183
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine. 2022;387:205–216. https://doi.org/10.1056/NEJMoa2206038
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. The New England Journal of Medicine. 2025. https://doi.org/10.1056/NEJMoa2416394
- U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
- U.S. Food and Drug Administration. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or